Stock profile

MONOPAR THERAPEUTICS INC (MNPR)

MNPR · Latest close — as of Oct 13, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
Data unavailable
No price in range
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RA Capital Management0.54%667,207HELD
Deerfield Management0.31%323,745HELD
OrbiMed Advisors0.27%157,423NEW

Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").

Short interest

Shares short · Sep 15, 2026844,226
Days to cover7.20

Shares short at recent settlements — Jun 30, 2026: 1.5M · Jul 15, 2026: 1.4M · Jul 31, 2026: 1.1M · Aug 14, 2026: 887K · Aug 31, 2026: 852K · Sep 15, 2026: 844K.

Source: FINRA Equity Short Interest (biweekly settlement data).

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the 90 days to Oct 14, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).

Screens & lenses

This stock does not currently pass any tracked screen.

Related stocks

Also held by the tracked funds that hold MNPR: Ascendis Pharma A/S (ASND) · Sionna Therapeutics, Inc. (SION) · Taysha Gene Therapies, Inc. (TSHA) · ARS Pharmaceuticals, Inc. (SPRY) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · TYRA BIOSCIENCES INC (TYRA) · DISC MEDICINE INC (IRON) · Praxis Precision Medicines, Inc. (PRAX) · BIOCRYST PHARMACEUTICALS INC (BCRX) · PRELUDE THERAPEUTICS INC (PRLD).

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.